Information  X 
Enter a valid email address

Tiziana Life Sci PLC (TILS)

  Print   

Wednesday 20 January, 2021

Tiziana Life Sci PLC

B. Riley Virtual Oncology Investor Conference

RNS Number : 3242M
Tiziana Life Sciences PLC
20 January 2021
 

Tiziana Life Sciences plc

("Tiziana" or the "Company")

 

Tiziana Life Sciences to Participate in a Fireside Chat at B. Riley Virtual Oncology Investor Conference:

on 21 January 2021 at 3 pm ET/8 pm GMT

 

NEW YORK and LONDON - 20 January 2021 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO and CSO, Dr. Kunwar Shailubhai, will participate in a fireside chat via a video link on Thursday 21 January 2021 at 3 pm ET / 8 pm GMT to provide updates on the Company. 

 

Date:

Thursday 21 January 2021

Time:

3 pm U.S. Eastern / 8 pm GMT

Webcast:

https://b-riley-oncology-investor-conference.events.issuerdirect.com/signup

 

About Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

 

For further enquiries:

 

United Kingdom Investors:

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and Founder

 

+44 (0)20 7495 2379

United States Investors:

Dave Gentry

RedChip Companies Inc.

 

Office 1 800 RED CHIP (733 2447)

Cell 407-491-4498 (USA)

[email protected]

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns[email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFBLFLFFLBBBX

a d v e r t i s e m e n t